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Abstract
There is a need to reduce the number of cystoscopies on patients with haematuria. Presently there are no reliable
biomarkers to screen for bladder cancer. In this paper, we evaluate a new simple in–house fabricated, GC-sensor
device in the diagnosis of bladder cancer based on volatiles. Sensor outputs from 98 urine samples were used to
build and test diagnostic models. Samples were taken from 24 patients with transitional (urothelial) cell carcinoma
(age 27-91 years, median 71 years) and 74 controls presenting with urological symptoms, but without a urological
malignancy (age 29-86 years, median 64 years); results were analysed using two statistical approaches to assess
the robustness of the methodology. A two-group linear discriminant analysis method using a total of 9 time points
(which equates to 9 biomarkers) correctly assigned 24/24 (100%) of cancer cases and 70/74 (94.6%) controls. Under
leave-one-out cross-validation 23/24 (95.8%) of cancer cases were correctly predicted with 69/74 (93.2%) of controls.
For partial least squares discriminant analysis, the correct leave-one-out cross-validation prediction values were
95.8% (cancer cases) and 94.6% (controls). These data are an improvement on those reported by other groups
studying headspace gases and also superior to current clinical techniques. This new device shows potential for the
diagnosis of bladder cancer, but the data must be reproduced in a larger study.
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Introduction
Over 10,000 patients are diagnosed with bladder cancer in
the UK annually and half will die of the disease [1]. Most
patients (80%) present with painless haematuria which must be
investigated [2]. Of those with visible haematuria 19% will have
bladder cancer while for non-visible haematuria the rate is just
5% [3]. Haematuria, although important, has a low pre-test
probability of diagnosing bladder cancer for which there are no
screening tests. Consequently, cystoscopy remains the gold
standard for detecting the disease in patients with haematuria
[4]. Cystoscopy is a frequently performed procedure and the
cost to the NHS, of investigating people found not to have
bladder cancer, is £33.5M per year [3], based on a tariff
currently of around £400. Cystoscopy is a costly, invasive and
undignified procedure. There is a need for an inexpensive, less
invasive alternative.
Bladder cancer cases presenting at an early stage can be
treated by transurethral resection without the need for major
extirpative surgery. Furthermore this early stage disease has
an excellent 5-year survival rate (>94%) compared to <50% 5-
year survival for more advanced disease, so a non-invasive
screening test that identifies cancer at an early stage from
urine headspace has the potential to revolutionise patient care.
Despite resection, the majority (50-70%) will recur and 10-30%
progress to advanced disease [5], consequently frequent
cystoscopy checks are necessary which account for 71% of the
costs of treating bladder cancer [6]. These factors mean that
bladder cancer is the most expensive cancer per patient to
manage [7]. Various mass screening options have been
considered, including the haematuria dipstick, NMP22, or
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UroVysion [8]. However, these biomarkers, as well as urine
cytology, lack sensitivity [9]. Currently, no biomarkers can be
recommended for clinical practice because of their poor
sensitivity and specificity, although there is some evidence that
biomarkers may be of use in monitoring recurrence or
screening high risk individuals [10]. New selective biomarker(s)
for bladder cancer would reduce diagnostic uncertainty and
surveillance-related morbidity. It could reduce costs and
improve patients’ quality of life by avoiding unnecessary
invasive diagnostic tests. It could also improve prognosis for
patients through earlier detection of potentially lethal disease
whilst decreasing the economic burden of haematuria clinics
[11]. There is some evidence to support the hypothesis that
bladder cancer is associated with the presence of specific
volatile organic compounds (VOCs) in the gas emitted from
urine samples. In 1999 Spanel et al. reported that
formaldehyde was more abundant in the urine of men with
bladder cancer than from those with prostate cancer and
healthy controls [12]. A study in which dogs were trained to
respond to the urine samples from patients with bladder cancer
gave a mean success rate of 41% compared to the 14%
expected by chance [13]. More recently the same group
reported that the best performing dog could identify 73% of
cancers [14]. Meanwhile, VOC analysis using e-nose
technology was found to have 70% sensitivity and specificity
for the diagnosis of bladder cancer from healthy controls,
dropping to 60% and 67% respectively when testing with urine
controls from patients with non-malignant urological diseases
[15]. In this report, we describe data from a pilot study which
shows the potential for a novel, in-house fabricated VOC
sensor device for accurately diagnosing bladder cancer.
Methods
Patient Recruitment
A total of 98 male patients, aged 27-91 years, presenting to
urology clinics in Bristol were recruited after obtaining informed
consent. All had undergone a clinical assessment for their
symptoms. Demographics for the patient groups studied are
given in Table 1; there were 3 controls per cancer patient. Each
patient provided a urine sample on the morning prior to their
examination or cystoscopy. Samples were classified when the
clinical assessment was completed. When bladder cancer
(n=24) was found, grade and stage of the cancer were
recorded (Table 2); the majority were well-differentiated or
intermediate grade (G1, G2) and at an early stage (Ta) confined
to the bladder lining. There were 74 controls, patients who
were undergoing investigation for symptoms of bladder outflow
obstruction and or haematuria; their symptoms and relevant co-
morbidities included: 31 had raised PSA without malignancy,
24 had hypertension, 19 had visible haematuria, 15 had
bladder outflow symptoms, 7 diabetes, 4 non-visible
haematuria, 2 had renal tract stones and 1 had undergone
renal transplant surgery.
Ethical approval for the study was obtained from the
Wiltshire Research Ethics Committee; each participant
reviewed an information sheet and gave written consent.
Sample storage
Aliquots of fresh urine (0.75 ml) were transferred to septum-
topped, glass headspace vials (Sigma Aldrich, Dorset, UK) and
were frozen at -20oC until analysis. In a previous study we
found that freezing had no detectable effect on the volatile
composition of the samples [16].
Headspace Analysis
Each urine sample was defrosted by immersing the vial in a
water bath at 60oC for 30 seconds. Thereafter, each sample
was treated with an equal volume (0.75 ml) of sodium
hydroxide (1M; Fisher Scientific, Leicestershire, UK) and the
mixture equilibrated at 60oC in a water bath for 50 minutes prior
to extraction of 2cm3 of headspace air. Headspace air was
extracted using an airtight Hamilton gas syringe (10ml, Fisher
Scientific, Leicestershire, UK) and was then immediately
injected into the inlet of a gas chromatograph coupled to a
sensor detection system.
The VOCs from urine samples were analyzed using an in-
house fabricated sensor system. The device comprised of a
conventional gas chromatography oven (Clarus 500,
PerkinElmer) fitted with a commercially available capillary
column (30 metre long SPBTM-1 SULFUR capillary column with
an inner diameter of 0.32 mm and a film thickness of 4 μm
(Sigma Aldrich, Dorset, UK)) which was interfaced to a heated
(450oC) metal oxide sensor used as the detector. The metal
oxide sensor consisted of a tin oxide, zinc oxide mix (50: 50 wt
Table 1.
Diagnosis
No. of
patients
Age range in years
(median) Smoking status
Bladder
cancer 24 27 – 91 (mean 71)
7 smokers; 17 non-
smokers (9 ex-smokers)
Control (non-
cancer) 74 29 – 86 (mean 64)
15 smokers; 59 non-
smokers (17 ex-smokers)
Table 2.
Tumour Tumour stage (TNM)
Grade TaN0Mx T1N0Mx T2N0Mx
G1 6 Nil Nil
G2 10 1 Nil
G3 1 5 1
The tumours were graded according to the WHO 1973 guidelines. G1: well
differentiated (look similar to the normal cells found in the bladder - slow growing
cancer) G2: intermediate level of differentiation (mixture of G1 & G3) G3: poorly
differentiated (looks very different from normal bladder cells – most aggressive).
Staging of the tumour is given according to the TNM (Tumour, Node, Metastasis)
criteria. Ta: the cancer is just in the innermost layer of the bladder lining. T1: the
cancer has started to grow into the connective tissue beneath the bladder lining.
T2: the cancer has grown through the connective tissue into the muscle. All
patients are also graded N0 (No regional lymph-node involvement) Mx (metastasis
status was not assessed).
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%). The sensor preparation and characterisation has been
reported elsewhere [17]. The GC injector was heated to a
preset temperature of 150oC and was fitted with a 1mm quartz
liner. Compressed air (BOC, Guilford, UK) was used as the
carrier gas at a pressure of 35 psi and was passed through an
air purifier (300ml SupelcarbTM Hydrocarbon trap, Sigma-
Aldrich, Dorset, UK). The GC temperature programme used
was as follows: initial GC oven temperature held at 30oC for 6
minutes, then ramped at a rate of 5oC/min to 100oC with a 22
minute hold, giving a total run time of 42 minutes.
The GC sensor system was calibrated daily using a certified
gas standard (1% tolerance) of 50 ppm ethanol in blended air
(Air Products Plc, Speciality Gases, Crewe CW1 6AP).
After headspace gas (2cm3) was injected into the device the
volatile compounds were separated according to their chemical
properties and eluted from the column at specific times.
Volatiles eluted from the column and impinged on the sensor.
The volatile compounds adsorbed and reacted on the heated
metal oxide surface of the sensor concomitantly producing a
reversible change in the electrical resistance. The change in
electrical resistance versus time profile for the sensor produced
a sample specific chromatogram. These resistance time
chromatograms were then interpreted statistically based on
their group membership.
Statistical analysis
Resistance was sampled at intervals of 0.5 seconds for 42
minutes (t = 1, 2,…. , 5040). The utility of highly specific
features of the profiles, low order frequencies in the profiles,
and broader profile features of the data in developing a good
classifier was investigated. As there is no gold standard
approach to data of this kind, we investigated two independent
methods of statistical analysis.
Methods 1 and 2 were based on standardizing each
resistance profile so that each had a mean value of 0 and a
standard deviation of 1 [15]. This transformation ensures each
donor profile is on the same scale permitting a fair comparison
between disease groups, invariant of scale and location effects,
whilst preserving the relative minima and maxima within each
profile. Statistical validation of models was undertaken using
leave-one-out cross-validation which provides an indication of
model robustness and predictive performance on fresh unseen
samples.
Method 1.  This was based on a between-groups
comparison of the standardized resistance profiles using two-
group linear discriminant analysis implementing the forward
stepwise selection algorithm to ensure a) the number of
predictors in the model does not exceed the smallest group
size and b) the inclusion of a predictor variable does not result
in multi-collinearity problems. The within-sample robustness of
the predictive properties of the derived model was assessed
using leave-one-out cross validation. This modelling strategy
was designed to investigate whether a simple parsimonious
description of between-groups separation existed based upon
highly specific differences in profiles between groups.
Method 2.  Partial least squares discriminant analysis (PLS-
DA) was used to build a two group classifier for the
discrimination of bladder cancer cases from controls. PLS-DA
is an established supervised classification technique used in
sensormetric analyses and is an information extraction and
data reduction technique designed to maximally separate two
or more groups and is particularly suited to high dimensional
and multi-collinear data. This approach is considered to be
better than alternative approaches using principal components
analysis over a wide range of classification problems [18]. In
this context, PLS-DA was considered from a proof-of-concept
aspect i.e. can a small number of latent factors extracted from
the entire data set discriminate between cases and controls.
We adopted an extraction procedure using up to ten latent
factors and used a leave-one-out classification to assess within
sample classification accuracy.
Results
Sensor outputs were compared in the two groups; patients
with bladder cancer (24) and patients without cancer (74). Two
independent statistical approaches were taken to determine
whether there were differences in the sensor output. For each
method, patients with cancer were compared with those
without; the sample size was too small to be able to compare
patterns with grade or stage (Table 1).
Figure 1 shows typical chromatograms of standardised
resistance versus time for two controls and two bladder cancer
patients. The chromatograms of the two bladder cancer patient
samples are broadly similar as are those of the two control
samples. However, it is apparent that the control samples differ
from the bladder cancer samples. The most obvious difference
is a peak at circa 3200 (half seconds) which is present in both
bladder cancer samples but absent from both controls.
Analysis of the chromatograms showed that 20/24 bladder
cancer samples had a measurable peak in this region. In the
control samples, peaks in this region of the spectra were
predominantly absent. To highlight this point, Figure 2 shows
overlaid averaged chromatograms for each group, clearly
showing the feature at 3200 half seconds in the bladder cancer
group, which is absent from the control group.
Figure 3 shows the retention time stability of the system for
three common peaks which span the retention time range
where the majority of the detected peaks elute. The data
shown are for 24 selected control samples (which span the full
7 month duration of the study) and the 24 bladder cancer
samples. There is no noticeable trend in terms of drift over time
(samples 1-24 controls and 25-48 bladder cancer are displayed
in run date order). There is a day to day fluctuation in the
measured retention times of circa ±1%. In addition an ethanol
standard was run daily in order to assess the retention time
and sensitivity of the system. The retention time of ethanol over
the course of the study had a mean of 329.2 half seconds (S.D.
3.97), in line with the results from the in sample peaks. The
average width of the peaks is circa 100 half seconds and can
be up to 200 half seconds at higher retention times. Therefore,
variability of approximately ±1% was found to have a negligible
effect on the predictive accuracy of the statistical models (see
section Statistical Analysis Method 1 below).
The average sensitivity to ethanol over a two month period
was 98.5% (S.D. 10.6) (R0-Rg/R0 ×100, where R0 is the
Bladder Cancer Found by Urine Headspace Analysis
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e69602
baseline resistance and Rg is the resistance when exposed to
ethanol). Although the sensitivity of the sensor was maintained
at a reasonably constant level the baseline resistance was
subject to drift. To counteract this effect and to aid visual and
statistical comparison of the results the resistance scale was
standardised using the methodology described above.
Statistical Analysis Method 1
A total of 9 time points were selected (t (sampling time
points) = 117, 153, 174, 201, 359, 1073, 1162, 1362, 3204).
Within samples 24/24 (100%) of bladder cancer cases and
70/74 (94.6%) controls were correctly assigned. This means
the model detected the cancer in all patients, irrespective of the
grade or stage. Under leave-one-out cross validation these
values fell to 23/24 (95.8%) and 69/74 (93.2%) correct
classification, respectively (Table 3). Other discriminant models
give similar predictive accuracy (e.g. the sampling time points t
= 117, 201, 231, 362, 1090, 1360, 3297, 3334, 3417 gives
cross-validated accuracy of 95.8% for bladder cancer cases,
and 94.6% for controls). This shows that the model is not
sensitive to specific “retention times”. It also shows that the
time points selected do not necessarily represent separate
peaks, but are simply time points where the two groups of
spectra differ maximally. In this second model 3 time points are
selected which span the broad peak present in the bladder
cancer group.
Statistical Analysis Method 2
The results of PLS-DA in terms of percentage correctly
classified within sample and in using leave-one-out
classification are given in Table 4 according to number of latent
factors extracted in the modelling process. The use of 7 or
more factors identified 23/24 of the patients with cancer: again
suggesting the diagnosis could be made in the vast majority of
patients, irrespective of the grade or stage of the cancer.
Figure 1.  Examples of chromatograms (standardised resistance vs. time) of the urine of two patients with bladder
cancer and two controls.  
doi: 10.1371/journal.pone.0069602.g001
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Discussion
A new technique is described for the identification of patients
with bladder cancer based on the profile of volatile organic
compounds emitted from their urine, using a GC combined with
a sensor system. The findings build on previous work using
dogs [14] and an electronic nose [15] which provide proof of
concept data for our findings.
Our findings are significantly better than those described
previously using the volatile analysis approach. The
improvement is probably the result of two factors: 1) use of the
chromatography separation step and 2) the adjustment of pH
using base. Base would have had several effects, the high
ionic strength would have driven VOCs into the headspace and
it would also have suppressed acids, increasing the
concentration of basic compounds in the headspace. Previous
work by our group has found that base treatment of urine
samples (compared to acid treatment or untreated samples),
enabled the identification of biomarkers that allowed
differentiation between prostate cancer and controls [19].
Sensor outputs were analyzed using two different,
independent data analysis techniques each of which showed
significant discrimination of samples from patients with and
without bladder cancer. Control samples were collected from
patients who had attended clinic with urological problems that
were later found to be non-malignant. The choice of controls is
important to assess the clinical usefulness of such a test.
Patients without cancer may present similar symptoms to those
with cancer and it is differentiating these that are the clinical
challenge. Others [15] have reported that patients with bladder
cancer could be differentiated from healthy controls with
greater certainty than controls from urology clinics. However,
we have specifically chosen controls recruited from the same
urology clinic: many of them had haematuria making them ideal
controls for this study.
Figure 2.  The averaged chromatograms for the bladder cancer group and the control group shown on the same
standardised resistance time plot.  
doi: 10.1371/journal.pone.0069602.g002
Bladder Cancer Found by Urine Headspace Analysis
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e69602
Two different statistical approaches were used, linear
discriminant analysis and partial least squares discriminant
analysis, however, both techniques used slices of the time
profile (bins). The results were similar; using 6 or more
components in the PLS-DA correctly identified over 90% of
cases and controls, while the simple linear DA correctly
classified over 93% of cases and controls.
A review of biomarkers for the detection and surveillance of
bladder cancers [20] gave sensitivity and specificity ranges,
respectively, for each marker as follows: bladder tumour
antigen (BTA), BTA Stat (Polymedco), 52.5%-78.0% and
69.0%–87.1%; BTA Trak (Polymedco), 51%-100% and 73%–
92.5%; cytology, 12.1%-84.6% and 78.0%–100%; hematuria
dipstick, 47.0%-92.6% and 51.0%–84.0%; nuclear matrix
protein (NMP), NMP22 Bladder Cancer Test (Matritech),
34.6%-100% and 60.0%–95.0%; NMP22 BladderChek
(Matritech), 49.5%-65.0% and 40.0%–89.8%; ImmunoCyt/uCyt
+ (DiagnoCure), 63.3%-84.9% and 62.0%–78.1%; ImmunoCyt/
uCyt+ and cytology, 81.0%-89.3% and 61.0%–77.7%; and
UroVysion (Abbott Molecular)/florescence in situ hybridization,
68.6%-100% and 65.0%–96.0%. As can be observed there is a
wide range of results. The review concluded that no currently
available bladder cancer urinary marker is sensitive enough to
eliminate the need for cystoscopy. A recently published
algorithm, combining tests, suggested this may increase
sensitivity and specificity to 91% and 80% respectively, but the
paper concluded that it remained a challenge to accurately
detect all bladder cancers [9]. Our technique for bladder tumour
diagnosis gives results that are comparable and, in some
cases, better than currently available urinary biomarkers for
bladder cancer. The GC-sensor approach is low cost and can
be used by semi-skilled personnel. The sensor is relatively
inexpensive to fabricate and its lifetime is likely to be far in
Table 3. Classification results using two-group linear
discriminant analysis.
  Predicted group membership
  Bladder cancer (%)Control (%)Total
Original model Bladder cancer 24 (100) 0 (0) 24
 Control 4 (5.4) 70 (94.6) 74
Cross-validation
(leave-one-out) Bladder cancer 23 (95.8) 1 (4.2) 24
 Control 5 (6.8) 69 (93.2) 74
Figure 3.  The retention time stability of three common peaks from 24 selected control samples and the 24 bladder cancer
samples, in date order.  There is a minimal day to day fluctuation circa ± 1%.
doi: 10.1371/journal.pone.0069602.g003
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excess of 100 analyses. Furthermore the components are
capable of further miniaturization to produce a point of care
device. For example miniaturised GC systems already exist
that make use of microelectromechanical system (MEMS)
components [21]. The combination of the GC separation
element and sensor element on a MEMS platform is also an
active area of research [22,23]. The current device uses a
minimal temperature ramp but it may be possible to perform
the separation isothermally at ambient temperatures. It also
uses air as the carrier gas introducing the possibility of using a
compressor with appropriate filters instead of gas cylinders.
The reason for the presence of volatile biomarkers is
probably a change in metabolism by malignant cells. There is
evidence for oxidative stress and induction of cytochrome P450
by lung, breast, and prostate cancers [24-27]; this is associated
with a change in exhaled VOCs from patients with lung and
breast cancer [24,25]. Studies of bladder cancer have also
found altered enzymatic activity [28] as well as abnormalities of
the citric acid cycle [29], resulting in increased conversion of
pyruvic acid to lactic acid. How these two examples result in
the production of VOCs is not clear, but they serve to illustrate
that there are abnormalities of particular metabolic pathways
with specific changes in metabolites as a result. In the case of
the bladder, the proximity of malignant cells to urine is likely to
result in abnormal VOC patterns in urine of patients with
bladder cancer. In summary the use of the GC-sensor system
for detection of VOC profiles speeds up the process of data
analysis compared to the much more laborious and expensive
systems such as GCMS which also require highly experienced
researchers.
The identity of the VOCs that contribute to the biomarker
profile has yet to be determined. Their characterisation may be
defined in future work using gas chromatography mass
spectrometry techniques and this will provide further insight
into bladder cancer induced biochemical changes.
The study is a small scale prospective investigation based
around the intuitively appealing proposition of the existence of
some systematic compositional differences in urine samples
Table 4. Discrimination of bladder cancer cases from
controls using PLS-DA.
Number of latent factors Predicted correct Predicted correct
 Within sample Leave-one-out
 Bladder (%) Control (%) Bladder (%) Control (%)
1 19 (79.2) 46 (62.2) 19 (79.2) 46 (62.2)
2 18 (75) 60 (81.1) 18 (75) 59 (79.7)
3 21 (87.5) 63 (85.5) 20 (83.3) 64 (86.5)
4 21 (87.5) 64 (86.5) 21 (87.5) 64 (86.5)
5 23 (95.8) 62 (83.8) 23 (95.8) 61 (82.4)
6 22 (91.7) 68 (91.9) 21 (87.5) 67 (90.5)
7 23 (95.8) 70 (94.6) 23 (95.8) 67 (90.5)
8 23 (95.8) 70 (94.6) 23 (95.8) 69 (93.2)
9 23 (95.8) 71 (95.9) 23 (95.8) 71 (95.9)
10 23 (95.8) 71 (95.9) 23 (95.8) 70 (94.6)
Abbreviation: PLS-DA, partial least squares discriminant analysis
between those patients with, and those patients without,
bladder cancer. In this research the treated urine samples are
quantitatively characterised using a reliable in-house fabricated
sensor coupled with gas chromatographic separation.
The research is particularly challenging and retains good
ecological validity by not using healthy controls. Results are
extremely encouraging. However, the relatively small sample
size is based on patients from a single centre and population
coverage and external validity cannot be assured;
consequently some caution must be exercised with regard to
generalising beyond the sample. It is also recognised that the
robustness of statistical models based on small sample sizes
could be prone to the presence of any chance idiosyncratic
sample features, and the relatively small sample sizes do not
readily permit stratification on potentially important patient
features (e.g. tumour size). Equally the small sample size does
not allow a proper statistical assessment of the effects of other
confounding factors such as smoking status, drug treatments,
ethnicity etc. In addition an all male cohort was selected as the
basis of the study, this removes a confounding factor but is a
limitation of the current study despite a much higher incidence
of this cancer in the male vs. female population (circa 2.5:1).
Another limitation of the current study concerns the use of
frozen samples, although we have collected robust data from
GC-MS studies that freezing does not have a marked effect on
the volatile profile [16]. In terms of the device, the long term
stability of the sensor and retention time drift are potential
limitations. The use of certified gas standards in this study
ensured that the sensitivity of the sensor was regularly
monitored and maintained at a comparable level. Retention
time was subject to fluctuations of ±1%, this was assessed by
measuring common peaks in the sample and the retention time
of the ethanol standard over time. As the peaks in the
chromatogram are relatively broad (when compared to the
possible error) and the statistical model is not dependent on
identifying single peaks with specific retention times, we are
confident that this error does not unduly affect the current
analysis. In longer term studies a standard mixture of
compounds spanning the retention time range could be
substituted for ethanol, allowing for correction of any drift.
Leave-one-out cross validation coupled with the triangulation
of results from markedly different statistical analysis techniques
provide good prima facie support for the broad claim of
differences between groups within the collected samples.
Conclusion
The novel combination of a GC and a unique metal oxide
sensor based device has provided data to underpin a new
instrument for the diagnosis of bladder cancer. The statistical
model could be easily used to write an algorithm that will
display the diagnosis. Both of the models tested were 96%
accurate in diagnosing bladder cancer. These data must now
be reproduced in larger studies.
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